<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02766608</url>
  </required_header>
  <id_info>
    <org_study_id>PT009002</org_study_id>
    <nct_id>NCT02766608</nct_id>
  </id_info>
  <brief_title>Study to Assess Efficacy and Safety of PT009 Compared to PT005, PT008, and Symbicort® Turbuhaler® on Lung Function Over 24-Weeks in Subjects With Moderate to Very Severe COPD</brief_title>
  <acronym>telos</acronym>
  <official_title>A Randomized, Double-Blind, Parallel Group, Multi-Center Study to Assess the Efficacy and Safety of PT009 Compared to PT005, PT008, and Open-label Symbicort® Turbuhaler®, as an Active Control, on Lung Function Over a 24-Week Treatment Period in Subjects With Moderate to Very Severe COPD</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pearl Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pearl Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase III randomized, double-blind, parallel group, multi-center, 24-week lung
      function study with BFF MDI (320/9.6 μg and 160/9.6 μg) compared to FF MDI 9.6 μg, BD MDI 320
      μg, and open-label Symbicort® TBH (200/6 μg) administered BID.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase III randomized, double-blind, parallel group, multi-center, 24-week lung
      function study with BFF MDI (320/9.6 μg and 160/9.6 μg) compared to FF MDI 9.6 μg, BD MDI 320
      μg, and open-label Symbicort® TBH (200/6 μg) administered BID. Subjects will undergo a 1- to
      4-week Screening Period. Subjects who successfully complete the Screening Period will be to
      one of the following five treatment groups:BFF MDI 320/9.6 μg BID (N=660), BFF MDI 160/9.6 μg
      BID, FF MDI 9.6 μg BID, BD MDI 320 μg BID, Symbicort®, TBH 400/12 μg BID. Following
      randomization, subjects will enter the Treatment Period and undergo additional treatment
      visits over 24 weeks.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 31, 2016</start_date>
  <completion_date type="Actual">December 1, 2017</completion_date>
  <primary_completion_date type="Actual">December 1, 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI Versus FF MDI)</measure>
    <time_frame>at Week 24</time_frame>
    <description>Change from baseline in morning pre-dose trough FEV1 (Forced expiratory volume in 1 second) at Week 24 (BFF MDI versus FF MDI)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change From Baseline in FEV1 AUC0-4 (BFF MDI vs BD MDI)</measure>
    <time_frame>at Week 24</time_frame>
    <description>Changes from baseline in FEV1 AUC0-4 were normalized by taking the area under the curve value and dividing by the length of time under consideration (usually 4 hours). This normalization represents a weighted average of the change from baseline in FEV1 over the 4-hour period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to First Moderate or Severe COPD Exacerbation (BFF MDI vs FF MDI).</measure>
    <time_frame>over 24 Weeks (timepoints of 4, 12 &amp; 20 weeks)</time_frame>
    <description>Time to first moderate or severe COPD (Chronic Obstructive Pulmonary Disease) exacerbation (BFF MDI vs FF MDI).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Achieving an MCID (Minimal Clinically Important Difference) of 4 Units or More in SGRQ at Week 24</measure>
    <time_frame>at Week 24</time_frame>
    <description>The SGRQ (St. George's Respiratory Questionnaire) is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of BFF MDI, FF MDI, BD MDI, &amp; Symbicort TBH on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI vs BD MDI)</measure>
    <time_frame>at Week 24</time_frame>
    <description>Change from baseline in morning pre-dose trough FEV1(Forced Expiratory Volume in 1 second) at Week 24 (BFF MDI vs BD MDI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Change From Baseline in FEV1 at Week 24 (BFF MDI vs BD MDI)</measure>
    <time_frame>at Week 24</time_frame>
    <description>Peak change from baseline in FEV1 (Forced Expiratory Volume in 1 second) at Week 24 (BFF MDI vs BD MDI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Average Daily Rescue Ventolin HFA Use Over 24 Weeks (BFF MDI vs BD MDI)</measure>
    <time_frame>over 24 Weeks</time_frame>
    <description>Change from baseline in average daily rescue Ventolin HFA use over 24 weeks (BFF MDI vs BD MDI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 on Day 1, 5 Minutes, Time to Onset of Action Determination</measure>
    <time_frame>Day 1 - 5 Minutes</time_frame>
    <description>Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 on Day 1, 15 Minutes, Time to Onset of Action Determination</measure>
    <time_frame>Day 1 - 15 Minutes</time_frame>
    <description>Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 on Day 1, 30 Minutes, Time to Onset of Action Determination</measure>
    <time_frame>Day 1 - 30 Minutes</time_frame>
    <description>Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 on Day 1, 1 Hour, Time to Onset of Action Determination</measure>
    <time_frame>Day 1 - 1 Hour</time_frame>
    <description>Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 on Day 1, 2 Hours, Time to Onset of Action Determination</measure>
    <time_frame>Day 1 - 2 Hours</time_frame>
    <description>Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>FEV1 on Day 1, 4 Hours, Time to Onset of Action Determination</measure>
    <time_frame>Day 1 - 4 Hours</time_frame>
    <description>Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Substudy: 12-hour PFT Endpoint FEV1 AUC0-12</measure>
    <time_frame>at Week 12</time_frame>
    <description>Substudy: 12-hour PFT (Pulmonary Function Test) endpoint FEV1 (Forced Expiratory Volume) AUC0-12 (Area under the Curve 0-12). Changes from baseline in FEV1 AUC0-12 were normalized by taking the area under the curve value and dividing by the length of time under consideration. This normalization represents a weighted average of the change from baseline in FEV1 over the 12-hour period.</description>
  </other_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">2389</enrollment>
  <condition>Chronic Obstructive Pulmonary Disorder</condition>
  <arm_group>
    <arm_group_label>BFF MDI 320/9.6 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide and Formoterol Fumarate Inhalation Aerosol 160/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BFF MDI 160/9.6 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide and Formoterol Fumarate Inhalation Aerosol-80/4.8 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>FF MDI 9.6 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Formoterol Fumarate Inhalation Aerosol-4.8 μg per actuation MDI/ 120 inhalations Taken as 2 inhalations BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BD MDI 320 μg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Budesonide inhalation Aerosol 160 μg per actuation MDI/120 inhalations Taken as 2 inhalations BID</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Symbicort® TBH 400/12 μg</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Symbicort Turbuhaler 400/12 μg Taken as 2 inhalations BID</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BFF MDI 320/9.6 μg</intervention_name>
    <description>Blinded Treatment</description>
    <arm_group_label>BFF MDI 320/9.6 μg</arm_group_label>
    <other_name>Budesonide and Formoterol Fumarate Inhalation Aerosol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BFF MDI 160/9.6 μg</intervention_name>
    <description>Blinded Treatment</description>
    <arm_group_label>BFF MDI 160/9.6 μg</arm_group_label>
    <other_name>Budesonide and Formoterol Fumarate Inhalation Aerosol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FF MDI 9.6 μg</intervention_name>
    <description>Blinded Treatment</description>
    <arm_group_label>FF MDI 9.6 μg</arm_group_label>
    <other_name>Formoterol Fumarate Inhalation Aerosol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BD MDI 320 μg</intervention_name>
    <description>Blinded Treatment</description>
    <arm_group_label>BD MDI 320 μg</arm_group_label>
    <other_name>Budesonide Inhalation Aerosol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Symbicort® TBH 400/12 μg BID</intervention_name>
    <description>Open Label</description>
    <arm_group_label>Symbicort® TBH 400/12 μg</arm_group_label>
    <other_name>Symbicort® Turbuhaler</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Give their signed written informed consent to participate

          2. Are at least 40 years of age and no older than 80 years

          3. COPD patients who are symptomatic

          4. Must be receiving one or more inhaled bronchodilators as maintenance therapy

        Exclusion Criteria:

          1. Current diagnosis of asthma,

          2. COPD due to α1-Antitrypsin Deficiency

          3. Known active tuberculosis, lung cancer, cystic fibrosis, significant bronchiectasis,
             Pulmonary resection or Lung Volume Reduction Surgery during the past 6 months

          4. Long-term-oxygen therapy (≥ 12 hours a day).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Athens</city>
        <state>Alabama</state>
        <zip>35611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dothan</city>
        <state>Alabama</state>
        <zip>36305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85006</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85745</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gold River</city>
        <state>California</state>
        <zip>95670</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Palm Springs</city>
        <state>California</state>
        <zip>92262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95823</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boulder</city>
        <state>Colorado</state>
        <zip>80301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Colorado Springs</city>
        <state>Colorado</state>
        <zip>80907</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Littleton</city>
        <state>Colorado</state>
        <zip>80127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamden</city>
        <state>Connecticut</state>
        <zip>06517</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Clearwater</city>
        <state>Florida</state>
        <zip>33765</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>DeLand</city>
        <state>Florida</state>
        <zip>32720</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>33016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33175</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33186</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Panama City</city>
        <state>Florida</state>
        <zip>32405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32127</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Port Orange</city>
        <state>Florida</state>
        <zip>32129</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winter Park</city>
        <state>Florida</state>
        <zip>32789-4681</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Blue Ridge</city>
        <state>Georgia</state>
        <zip>30513</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83646</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Towson</city>
        <state>Maryland</state>
        <zip>21204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Westminster</city>
        <state>Maryland</state>
        <zip>21157</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>North Dartmouth</city>
        <state>Massachusetts</state>
        <zip>02747</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Farmington Hills</city>
        <state>Michigan</state>
        <zip>48336</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edina</city>
        <state>Minnesota</state>
        <zip>55435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Woodbury</city>
        <state>Minnesota</state>
        <zip>55125</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Charles</city>
        <state>Missouri</state>
        <zip>63301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Henderson</city>
        <state>Nevada</state>
        <zip>89052</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89118</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jackson Heights</city>
        <state>New York</state>
        <zip>11236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Larchmont</city>
        <state>New York</state>
        <zip>10803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gastonia</city>
        <state>North Carolina</state>
        <zip>28054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Huntersville</city>
        <state>North Carolina</state>
        <zip>28078</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Fargo</city>
        <state>North Dakota</state>
        <zip>58103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43215</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45459</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Dublin</city>
        <state>Ohio</state>
        <zip>43016</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grove City</city>
        <state>Ohio</state>
        <zip>43123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Medford</city>
        <state>Oregon</state>
        <zip>97504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15243</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anderson</city>
        <state>South Carolina</state>
        <zip>29621</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Easley</city>
        <state>South Carolina</state>
        <zip>29640</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gaffney</city>
        <state>South Carolina</state>
        <zip>29341</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29615</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Indian Land</city>
        <state>South Carolina</state>
        <zip>29707</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mount Pleasant</city>
        <state>South Carolina</state>
        <zip>29464</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rock Hill</city>
        <state>South Carolina</state>
        <zip>29732</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seneca</city>
        <state>South Carolina</state>
        <zip>29678</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Union</city>
        <state>South Carolina</state>
        <zip>29379</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Johnson City</city>
        <state>Tennessee</state>
        <zip>37601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kingsport</city>
        <state>Tennessee</state>
        <zip>37660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Channelview</city>
        <state>Texas</state>
        <zip>77530</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Live Oak</city>
        <state>Texas</state>
        <zip>78233</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>New Braunfels</city>
        <state>Texas</state>
        <zip>78130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sugar Land</city>
        <state>Texas</state>
        <zip>77479</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>South Burlington</city>
        <state>Vermont</state>
        <zip>05403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Newport News</city>
        <state>Virginia</state>
        <zip>23606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bellevue</city>
        <state>Washington</state>
        <zip>98007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tacoma</city>
        <state>Washington</state>
        <zip>98405</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6L 5X8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Winnipeg</city>
        <state>Manitoba</state>
        <zip>R2K 3S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Truro</city>
        <state>Nova Scotia</state>
        <zip>B2N 1L2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ajax</city>
        <state>Ontario</state>
        <zip>L1S 2J5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Burlington</city>
        <state>Ontario</state>
        <zip>L7M 4Y1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sudbury</city>
        <state>Ontario</state>
        <zip>P3A 1W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M3J 2C5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 1T3</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8X 5A6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Mirabel</city>
        <state>Quebec</state>
        <zip>J7J 2K8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H1M 1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pointe-Claire</city>
        <state>Quebec</state>
        <zip>H9R 3J1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Charles Borromee</city>
        <state>Quebec</state>
        <zip>J6E 2B4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trois-Rivières</city>
        <state>Quebec</state>
        <zip>G8T 7A1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Victoriaville</city>
        <state>Quebec</state>
        <zip>G6P 6P6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1G 3Y8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G1W 4R4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Quebec</city>
        <zip>G3K 2P8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Boskovice</city>
        <zip>680 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Brandys nad Labem</city>
        <zip>250 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jindrichuv Hradec</city>
        <zip>37701</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Liberec</city>
        <zip>525947</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lovosice</city>
        <zip>410 02</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novy Bor</city>
        <zip>473 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava-Hrabuvka</city>
        <zip>700 30</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrava-Poruba</city>
        <zip>708 68</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Prague</city>
        <zip>15000</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 6</city>
        <zip>16900</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha 9</city>
        <zip>190 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha</city>
        <zip>140 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Praha</city>
        <zip>140 59</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rokycany</city>
        <zip>337 22</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Strakonice</city>
        <zip>38601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Teplice</city>
        <zip>415 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Varnsdorf</city>
        <zip>407 47</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zatec</city>
        <zip>43801</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bamberg</city>
        <zip>96049</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10119</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10629</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>10787</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>12157</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>13156</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Berlin</city>
        <zip>14059</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Darmstadt</city>
        <zip>64283</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Essen</city>
        <zip>45355</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Frankfurt</city>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20253</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20354</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Köln</city>
        <zip>51069</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04109</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Leipzig</city>
        <zip>04207</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lübeck</city>
        <zip>23552</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rodgau-Dudenhofen</city>
        <zip>63110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Schwerin</city>
        <zip>19055</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Balassagyarmat</city>
        <zip>2660</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Budapest</city>
        <zip>1135</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Cegléd</city>
        <zip>2700</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Csorna</city>
        <zip>9300</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gödöllő</city>
        <zip>2100</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hajdúnánás</city>
        <zip>4080</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Hatvan</city>
        <zip>3000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Komárom</city>
        <zip>2900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Makó</city>
        <zip>6900</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3529</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nyíregyháza</city>
        <zip>4400</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pécs</city>
        <zip>7626</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pécs</city>
        <zip>7635</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Siófok</city>
        <zip>8600</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szeged</city>
        <zip>H-6722</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szolnok</city>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Százhalombatta</city>
        <zip>2440</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Anyang-si</city>
        <zip>14068</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Busan</city>
        <zip>49201</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Incheon</city>
        <zip>21431</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Jeonju-si</city>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seongnam-si</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>02559</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>02841</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03181</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>04401</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>04551</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Seoul</city>
        <zip>08308</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Białystok</city>
        <zip>15-003</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Białystok</city>
        <zip>15-044</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Białystok</city>
        <zip>15-430</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bielsko-Biała</city>
        <zip>43-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chełm</city>
        <zip>22-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Elbląg</city>
        <zip>82-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Gdańsk</city>
        <zip>80-952</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Grudziądz</city>
        <zip>86-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Katowice</city>
        <zip>40-648</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kościan</city>
        <zip>64-000</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <zip>30-901</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kraków</city>
        <zip>31-159</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Legnica</city>
        <zip>59-220</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Lublin</city>
        <zip>20-093</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nowy Duninow</city>
        <zip>09-505</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrowiec Świętokrzyski</city>
        <zip>27-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ostrów Wielkopolski</city>
        <zip>63-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Piekary Śląskie</city>
        <zip>41-94O</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pila</city>
        <zip>64-920</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznań</city>
        <zip>60-685</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznań</city>
        <zip>60-693</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Poznań</city>
        <zip>60-823</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Proszowice</city>
        <zip>32-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Puławy</city>
        <zip>24-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ruda Slaska</city>
        <zip>41-709</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-051</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rzeszów</city>
        <zip>35-205</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Siedlce</city>
        <zip>08-110</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Sochaczew</city>
        <zip>96-500</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Suwałki</city>
        <zip>16-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Szczecin</city>
        <zip>70-111</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Tarnów</city>
        <zip>33-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Trzebnica</city>
        <zip>55-100</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>01-518</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Warszawa</city>
        <zip>02-777</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wieluń</city>
        <zip>98-300</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wołomin</city>
        <zip>05-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Wrocław</city>
        <zip>53-301</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zabrze</city>
        <zip>41-800</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Zamość</city>
        <zip>22-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <zip>90-141</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Łódź</city>
        <zip>91-363</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barnaul</city>
        <zip>656045</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Chelyabinsk</city>
        <zip>454106</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ivanovo</city>
        <zip>153005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Izhevsk</city>
        <zip>426035</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kazan</city>
        <zip>420008</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kazan</city>
        <zip>420012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Kirov</city>
        <zip>610027</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>123423</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>123995</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>125315</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Moscow</city>
        <zip>129090</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nizhny Novgorod</city>
        <zip>603126</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630008</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630051</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630087</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omsk</city>
        <zip>644043</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Omsk</city>
        <zip>644112</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Penza</city>
        <zip>440026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Penza</city>
        <zip>440067</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Perm</city>
        <zip>614000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pytigorsk</city>
        <zip>357538</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rostov-na-Donu</city>
        <zip>344068</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ryazan</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194044</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194354</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196601</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197342</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>198260</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>196084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>196143</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saint-Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Saratov</city>
        <zip>410012</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St-Petersburg</city>
        <zip>193231</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>196247</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>197089</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ulyanovsk</city>
        <zip>432009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Vladimir</city>
        <zip>600023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Voronezh</city>
        <zip>394066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150002</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yaroslavl</city>
        <zip>150062</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>620039</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Yekaterinburg</city>
        <zip>620149</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4181&amp;filename=PT009002_TELOS_PROTOCOL_REDACTED_07AUG2018_PDFA.pdf</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4181&amp;filename=d7820c00001-12-1-09-Final_sap_PDFA.pdf</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4181&amp;filename=PT009002_TELOS_PROTOCOL_REDACTED_PDFA.pdf</url>
    <description>Related Info</description>
  </link>
  <link>
    <url>http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_MED_7111&amp;studyid=4181&amp;filename=PT009002_Final_sap_Redacted_PDFA.pdf</url>
    <description>Related Info</description>
  </link>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>May 6, 2016</study_first_submitted>
  <study_first_submitted_qc>May 6, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 10, 2016</study_first_posted>
  <results_first_submitted>November 30, 2018</results_first_submitted>
  <results_first_submitted_qc>September 3, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">September 24, 2019</results_first_posted>
  <last_update_submitted>September 3, 2019</last_update_submitted>
  <last_update_submitted_qc>September 3, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COPD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Budesonide</mesh_term>
    <mesh_term>Formoterol Fumarate</mesh_term>
    <mesh_term>Budesonide, Formoterol Fumarate Drug Combination</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 24, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT02766608/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/08/NCT02766608/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study randomized subjects at 244 study centers in 7 countries, from June 2016 and November 2017. The study period was scheduled to take up to approximately 30 weeks for each individual subject from the time of screening through the follow-up period.</recruitment_details>
      <pre_assignment_details>Subjects were randomized in a 3:3:3:1:1 ratio to BFF 320/9.6, BFF 160/9.6, FF 9.6, BD 320, and Symbicort.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>BFF MDI 320/9.6 μg</title>
          <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 320/9.6 μg</description>
        </group>
        <group group_id="P2">
          <title>BFF MDI 160/9.6 μg</title>
          <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 160/9.6 μg</description>
        </group>
        <group group_id="P3">
          <title>FF MDI 9.6 μg</title>
          <description>Formoterol Fumarate Metered Dose Inhalation 9.6 μg</description>
        </group>
        <group group_id="P4">
          <title>BD MDI 320 μg</title>
          <description>Budesonide Metered Dose Inhalation 320 μg</description>
        </group>
        <group group_id="P5">
          <title>Symbicort TBH 400/12 μg</title>
          <description>Symbicort Turbuhaler 400/12 μg</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="655"/>
                <participants group_id="P2" count="637"/>
                <participants group_id="P3" count="644"/>
                <participants group_id="P4" count="206"/>
                <participants group_id="P5" count="219"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="576"/>
                <participants group_id="P2" count="567"/>
                <participants group_id="P3" count="554"/>
                <participants group_id="P4" count="169"/>
                <participants group_id="P5" count="190"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="79"/>
                <participants group_id="P2" count="70"/>
                <participants group_id="P3" count="90"/>
                <participants group_id="P4" count="37"/>
                <participants group_id="P5" count="29"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="22"/>
                <participants group_id="P3" count="17"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="21"/>
                <participants group_id="P2" count="20"/>
                <participants group_id="P3" count="24"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="15"/>
                <participants group_id="P3" count="32"/>
                <participants group_id="P4" count="8"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="5"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol disc criteria</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Administrative Reasons</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>The Modified Intent-To-Treat (mITT) Population is a subset of the ITT Population, and is defined as all subjects with post-randomization data obtained prior to discontinuation from treatment. The Intent-To-Treat (ITT) Population is defined as all subjects who were randomized to treatment and received any amount of the study treatment.</population>
      <group_list>
        <group group_id="B1">
          <title>BFF MDI 320/9.6 μg</title>
          <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 320/9.6 μg</description>
        </group>
        <group group_id="B2">
          <title>BFF MDI 160/9.6 μg</title>
          <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 160/9.6 μg</description>
        </group>
        <group group_id="B3">
          <title>FF MDI 9.6 μg</title>
          <description>Formoterol Fumarate Metered Dose Inhalation 9.6 μg</description>
        </group>
        <group group_id="B4">
          <title>BD MDI 320 μg</title>
          <description>Budesonide Metered Dose Inhalation 320 μg</description>
        </group>
        <group group_id="B5">
          <title>Symbicort TBH 400/12 μg</title>
          <description>Symbicort Turbuhaler 400/12 μg</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="664"/>
            <count group_id="B2" value="649"/>
            <count group_id="B3" value="648"/>
            <count group_id="B4" value="209"/>
            <count group_id="B5" value="219"/>
            <count group_id="B6" value="2389"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>mITT</population>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="655"/>
                    <count group_id="B2" value="637"/>
                    <count group_id="B3" value="644"/>
                    <count group_id="B4" value="206"/>
                    <count group_id="B5" value="219"/>
                    <count group_id="B6" value="2361"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64.2" spread="7.7"/>
                    <measurement group_id="B2" value="64.3" spread="7.6"/>
                    <measurement group_id="B3" value="64.1" spread="8.0"/>
                    <measurement group_id="B4" value="64.2" spread="7.4"/>
                    <measurement group_id="B5" value="65.3" spread="7.0"/>
                    <measurement group_id="B6" value="64.3" spread="7.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Values listed are mITT population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="655"/>
                    <count group_id="B2" value="637"/>
                    <count group_id="B3" value="644"/>
                    <count group_id="B4" value="206"/>
                    <count group_id="B5" value="219"/>
                    <count group_id="B6" value="2361"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="253"/>
                    <measurement group_id="B2" value="260"/>
                    <measurement group_id="B3" value="261"/>
                    <measurement group_id="B4" value="81"/>
                    <measurement group_id="B5" value="78"/>
                    <measurement group_id="B6" value="933"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="402"/>
                    <measurement group_id="B2" value="377"/>
                    <measurement group_id="B3" value="383"/>
                    <measurement group_id="B4" value="125"/>
                    <measurement group_id="B5" value="141"/>
                    <measurement group_id="B6" value="1428"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Values listed are mITT population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="655"/>
                    <count group_id="B2" value="637"/>
                    <count group_id="B3" value="644"/>
                    <count group_id="B4" value="206"/>
                    <count group_id="B5" value="219"/>
                    <count group_id="B6" value="2361"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="18"/>
                    <measurement group_id="B3" value="21"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="69"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="637"/>
                    <measurement group_id="B2" value="616"/>
                    <measurement group_id="B3" value="623"/>
                    <measurement group_id="B4" value="198"/>
                    <measurement group_id="B5" value="212"/>
                    <measurement group_id="B6" value="2286"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <population>mITT</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Values listed are mITT population</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="655"/>
                    <count group_id="B2" value="637"/>
                    <count group_id="B3" value="644"/>
                    <count group_id="B4" value="206"/>
                    <count group_id="B5" value="219"/>
                    <count group_id="B6" value="2361"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="9"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="71"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="633"/>
                    <measurement group_id="B2" value="619"/>
                    <measurement group_id="B3" value="622"/>
                    <measurement group_id="B4" value="197"/>
                    <measurement group_id="B5" value="210"/>
                    <measurement group_id="B6" value="2281"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI Versus FF MDI)</title>
        <description>Change from baseline in morning pre-dose trough FEV1 (Forced expiratory volume in 1 second) at Week 24 (BFF MDI versus FF MDI)</description>
        <time_frame>at Week 24</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BFF MDI 320/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 320/9.6 μg</description>
          </group>
          <group group_id="O2">
            <title>BFF MDI 160/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 160/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI 9.6 μg</title>
            <description>Formoterol Fumarate Metered Dose Inhalation 9.6 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI Versus FF MDI)</title>
          <description>Change from baseline in morning pre-dose trough FEV1 (Forced expiratory volume in 1 second) at Week 24 (BFF MDI versus FF MDI)</description>
          <population>mITT</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="571"/>
                <count group_id="O2" value="564"/>
                <count group_id="O3" value="550"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.036" lower_limit="0.019" upper_limit="0.053"/>
                    <measurement group_id="O2" value="0.017" lower_limit="0.000" upper_limit="0.034"/>
                    <measurement group_id="O3" value="-0.003" lower_limit="-0.020" upper_limit="0.015"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Change From Baseline in FEV1 AUC0-4 (BFF MDI vs BD MDI)</title>
        <description>Changes from baseline in FEV1 AUC0-4 were normalized by taking the area under the curve value and dividing by the length of time under consideration (usually 4 hours). This normalization represents a weighted average of the change from baseline in FEV1 over the 4-hour period.</description>
        <time_frame>at Week 24</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BFF MDI 320/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 320/9.6 μg</description>
          </group>
          <group group_id="O2">
            <title>BFF MDI 160/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 160/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI 9.6 ug</title>
            <description>Formoterol Fumarate Metered Dose Inhalation 9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>BD MDI 320 ug</title>
            <description>Budesonide Metered Dose Inhalation 320 μg</description>
          </group>
          <group group_id="O5">
            <title>Symbicort TBH 400/12 ug</title>
            <description>Symbicort Turbuhaler 400/12 ug</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in FEV1 AUC0-4 (BFF MDI vs BD MDI)</title>
          <description>Changes from baseline in FEV1 AUC0-4 were normalized by taking the area under the curve value and dividing by the length of time under consideration (usually 4 hours). This normalization represents a weighted average of the change from baseline in FEV1 over the 4-hour period.</description>
          <population>mITT</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="571"/>
                <count group_id="O2" value="565"/>
                <count group_id="O3" value="549"/>
                <count group_id="O4" value="168"/>
                <count group_id="O5" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.194" lower_limit="0.177" upper_limit="0.212"/>
                    <measurement group_id="O2" value="0.179" lower_limit="0.161" upper_limit="0.197"/>
                    <measurement group_id="O3" value="0.161" lower_limit="0.143" upper_limit="0.179"/>
                    <measurement group_id="O4" value="0.022" lower_limit="-0.011" upper_limit="0.054"/>
                    <measurement group_id="O5" value="0.187" lower_limit="0.157" upper_limit="0.218"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to First Moderate or Severe COPD Exacerbation (BFF MDI vs FF MDI).</title>
        <description>Time to first moderate or severe COPD (Chronic Obstructive Pulmonary Disease) exacerbation (BFF MDI vs FF MDI).</description>
        <time_frame>over 24 Weeks (timepoints of 4, 12 &amp; 20 weeks)</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BFF MDI 320/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 320/9.6 μg</description>
          </group>
          <group group_id="O2">
            <title>BFF MDI 160/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 160/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI 9.6 μg</title>
            <description>Formoterol Fumarate Metered Dose Inhalation 9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>BD MDI 320 μg</title>
            <description>Budesonide Metered Dose Inhalation 320 μg</description>
          </group>
          <group group_id="O5">
            <title>Symbicort TBH 400/12 ug</title>
            <description>Symbicort Turbuhaler 400/12 ug</description>
          </group>
        </group_list>
        <measure>
          <title>Time to First Moderate or Severe COPD Exacerbation (BFF MDI vs FF MDI).</title>
          <description>Time to first moderate or severe COPD (Chronic Obstructive Pulmonary Disease) exacerbation (BFF MDI vs FF MDI).</description>
          <population>mITT</population>
          <units>Percentage of Participants</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="655"/>
                <count group_id="O2" value="637"/>
                <count group_id="O3" value="644"/>
                <count group_id="O4" value="206"/>
                <count group_id="O5" value="219"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percentage of Subjects to Exacerbate at 4 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.2" lower_limit="2.1" upper_limit="4.9"/>
                    <measurement group_id="O2" value="3.3" lower_limit="2.2" upper_limit="5.1"/>
                    <measurement group_id="O3" value="5.5" lower_limit="4.0" upper_limit="7.6"/>
                    <measurement group_id="O4" value="7.0" lower_limit="4.2" upper_limit="11.5"/>
                    <measurement group_id="O5" value="1.8" lower_limit="0.7" upper_limit="4.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of Subjects to Exacerbate at 12 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9.8" lower_limit="7.7" upper_limit="12.4"/>
                    <measurement group_id="O2" value="9.9" lower_limit="7.8" upper_limit="12.5"/>
                    <measurement group_id="O3" value="15.0" lower_limit="12.4" upper_limit="18.1"/>
                    <measurement group_id="O4" value="14.9" lower_limit="10.6" upper_limit="20.7"/>
                    <measurement group_id="O5" value="8.6" lower_limit="5.5" upper_limit="13.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percentage of Subjects to Exacerbate at 20 Weeks</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.4" lower_limit="11.9" upper_limit="17.4"/>
                    <measurement group_id="O2" value="18.5" lower_limit="15.6" upper_limit="21.8"/>
                    <measurement group_id="O3" value="20.5" lower_limit="17.5" upper_limit="23.9"/>
                    <measurement group_id="O4" value="17.7" lower_limit="13.0" upper_limit="23.9"/>
                    <measurement group_id="O5" value="13.1" lower_limit="9.2" upper_limit="18.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Achieving an MCID (Minimal Clinically Important Difference) of 4 Units or More in SGRQ at Week 24</title>
        <description>The SGRQ (St. George's Respiratory Questionnaire) is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of BFF MDI, FF MDI, BD MDI, &amp; Symbicort TBH on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life.</description>
        <time_frame>at Week 24</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BFF MDI 320/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 320/9.6 μg</description>
          </group>
          <group group_id="O2">
            <title>BFF MDI 160/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 160/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI 9.6 μg</title>
            <description>Formoterol Fumarate Metered Dose Inhalation 9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>BD MDI 320 μg</title>
            <description>Budesonide Metered Dose Inhalation 320 μg</description>
          </group>
          <group group_id="O5">
            <title>Symbicort TBH 400/12 μg</title>
            <description>Symbicort Turbuhaler 400/12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Achieving an MCID (Minimal Clinically Important Difference) of 4 Units or More in SGRQ at Week 24</title>
          <description>The SGRQ (St. George's Respiratory Questionnaire) is a disease-specific questionnaire, self-completed by participants, used to evaluate the effect of BFF MDI, FF MDI, BD MDI, &amp; Symbicort TBH on health-related quality of life as compared to placebo in subjects with COPD. The scores range from 0 (minimum, best possible health status) to 100 (maximum, worst possible health status). The SGRQ contains 76 items grouped into three domains (symptoms, activity and impacts). Change from Baseline at a particular visit was calculated as the SGRQ total score at that visit minus Baseline. Change from Baseline in total score of -4 units or lower is considered as clinically meaningful improvement in quality of life.</description>
          <population>mITT</population>
          <units>Percentage of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="649"/>
                <count group_id="O2" value="635"/>
                <count group_id="O3" value="640"/>
                <count group_id="O4" value="204"/>
                <count group_id="O5" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48.12"/>
                    <measurement group_id="O2" value="47.22"/>
                    <measurement group_id="O3" value="41.59"/>
                    <measurement group_id="O4" value="43.62"/>
                    <measurement group_id="O5" value="53.78"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI vs BD MDI)</title>
        <description>Change from baseline in morning pre-dose trough FEV1(Forced Expiratory Volume in 1 second) at Week 24 (BFF MDI vs BD MDI)</description>
        <time_frame>at Week 24</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BFF MDI 320/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 320/9.6 μg</description>
          </group>
          <group group_id="O2">
            <title>BFF MDI 160/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 160/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI 9.6 μg</title>
            <description>Formoterol Fumarate Metered Dose Inhalation 9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>BD MDI 320 μg</title>
            <description>Budesonide Metered Dose Inhalation 320 μg</description>
          </group>
          <group group_id="O5">
            <title>Symbicort TBH 400/12 μg</title>
            <description>Symbicort Turbuhaler 400/12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Morning Pre-dose Trough FEV1 at Week 24 (BFF MDI vs BD MDI)</title>
          <description>Change from baseline in morning pre-dose trough FEV1(Forced Expiratory Volume in 1 second) at Week 24 (BFF MDI vs BD MDI)</description>
          <population>mITT</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="571"/>
                <count group_id="O2" value="564"/>
                <count group_id="O3" value="550"/>
                <count group_id="O4" value="168"/>
                <count group_id="O5" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.036" lower_limit="0.019" upper_limit="0.053"/>
                    <measurement group_id="O2" value="0.017" lower_limit="0.000" upper_limit="0.034"/>
                    <measurement group_id="O3" value="-0.003" lower_limit="-0.020" upper_limit="0.015"/>
                    <measurement group_id="O4" value="-0.028" lower_limit="-0.060" upper_limit="0.003"/>
                    <measurement group_id="O5" value="0.039" lower_limit="0.009" upper_limit="0.069"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Peak Change From Baseline in FEV1 at Week 24 (BFF MDI vs BD MDI)</title>
        <description>Peak change from baseline in FEV1 (Forced Expiratory Volume in 1 second) at Week 24 (BFF MDI vs BD MDI)</description>
        <time_frame>at Week 24</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BFF MDI 320/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 320/9.6 μg</description>
          </group>
          <group group_id="O2">
            <title>BFF MDI 160/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 160/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI 9.6 μg</title>
            <description>Formoterol Fumarate Metered Dose Inhalation 9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>BD MDI 320 μg</title>
            <description>Budesonide Metered Dose Inhalation 320 μg</description>
          </group>
          <group group_id="O5">
            <title>Symbicort TBH 400/12 μg</title>
            <description>Symbicort Turbuhaler 400/12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Peak Change From Baseline in FEV1 at Week 24 (BFF MDI vs BD MDI)</title>
          <description>Peak change from baseline in FEV1 (Forced Expiratory Volume in 1 second) at Week 24 (BFF MDI vs BD MDI)</description>
          <population>mITT</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="571"/>
                <count group_id="O2" value="565"/>
                <count group_id="O3" value="549"/>
                <count group_id="O4" value="168"/>
                <count group_id="O5" value="189"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.272" lower_limit="0.254" upper_limit="0.291"/>
                    <measurement group_id="O2" value="0.258" lower_limit="0.239" upper_limit="0.276"/>
                    <measurement group_id="O3" value="0.243" lower_limit="0.224" upper_limit="0.261"/>
                    <measurement group_id="O4" value="0.116" lower_limit="0.082" upper_limit="0.150"/>
                    <measurement group_id="O5" value="0.267" lower_limit="0.253" upper_limit="0.299"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Average Daily Rescue Ventolin HFA Use Over 24 Weeks (BFF MDI vs BD MDI)</title>
        <description>Change from baseline in average daily rescue Ventolin HFA use over 24 weeks (BFF MDI vs BD MDI)</description>
        <time_frame>over 24 Weeks</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BFF MDI 320/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 320/9.6 μg</description>
          </group>
          <group group_id="O2">
            <title>BFF MDI 160/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 160/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI 9.6 μg</title>
            <description>Formoterol Fumarate Metered Dose Inhalation 9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>BD MDI 320 μg</title>
            <description>Budesonide Metered Dose Inhalation 320 μg</description>
          </group>
          <group group_id="O5">
            <title>Symbicort TBH 400/12 μg</title>
            <description>Symbicort Turbuhaler 400/12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Average Daily Rescue Ventolin HFA Use Over 24 Weeks (BFF MDI vs BD MDI)</title>
          <description>Change from baseline in average daily rescue Ventolin HFA use over 24 weeks (BFF MDI vs BD MDI)</description>
          <population>mITT</population>
          <units>Puffs per day</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="654"/>
                <count group_id="O2" value="636"/>
                <count group_id="O3" value="641"/>
                <count group_id="O4" value="206"/>
                <count group_id="O5" value="218"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.3" lower_limit="-1.5" upper_limit="-1.1"/>
                    <measurement group_id="O2" value="-1.3" lower_limit="-1.4" upper_limit="-1.1"/>
                    <measurement group_id="O3" value="-1.1" lower_limit="-1.2" upper_limit="-0.9"/>
                    <measurement group_id="O4" value="-0.6" lower_limit="-0.9" upper_limit="-0.3"/>
                    <measurement group_id="O5" value="-1.2" lower_limit="-1.5" upper_limit="-0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 on Day 1, 5 Minutes, Time to Onset of Action Determination</title>
        <description>Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.</description>
        <time_frame>Day 1 - 5 Minutes</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BFF MDI 320/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 320/9.6 μg</description>
          </group>
          <group group_id="O2">
            <title>BFF MDI 160/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 160/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI 9.6 μg</title>
            <description>Formoterol Fumarate Metered Dose Inhalation 9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>BD MDI 320 μg</title>
            <description>Budesonide Metered Dose Inhalation 320 μg</description>
          </group>
          <group group_id="O5">
            <title>Symbicort TBH 400/12 μg</title>
            <description>Symbicort Turbuhaler 400/12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 on Day 1, 5 Minutes, Time to Onset of Action Determination</title>
          <description>Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.</description>
          <population>mITT</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="535"/>
                <count group_id="O2" value="536"/>
                <count group_id="O3" value="534"/>
                <count group_id="O4" value="171"/>
                <count group_id="O5" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.157" lower_limit="0.148" upper_limit="0.166"/>
                    <measurement group_id="O2" value="0.151" lower_limit="0.142" upper_limit="0.161"/>
                    <measurement group_id="O3" value="0.160" lower_limit="0.150" upper_limit="0.169"/>
                    <measurement group_id="O4" value="0.025" lower_limit="0.009" upper_limit="0.041"/>
                    <measurement group_id="O5" value="0.131" lower_limit="0.115" upper_limit="0.148"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 on Day 1, 15 Minutes, Time to Onset of Action Determination</title>
        <description>Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.</description>
        <time_frame>Day 1 - 15 Minutes</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BFF MDI 320/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 320/9.6 μg</description>
          </group>
          <group group_id="O2">
            <title>BFF MDI 160/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 160/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI 9.6 μg</title>
            <description>Formoterol Fumarate Metered Dose Inhalation 9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>BD MDI 320 μg</title>
            <description>Budesonide Metered Dose Inhalation 320 μg</description>
          </group>
          <group group_id="O5">
            <title>Symbicort TBH 400/12 μg</title>
            <description>Symbicort Turbuhaler 400/12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 on Day 1, 15 Minutes, Time to Onset of Action Determination</title>
          <description>Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.</description>
          <population>mITT</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="624"/>
                <count group_id="O2" value="615"/>
                <count group_id="O3" value="612"/>
                <count group_id="O4" value="203"/>
                <count group_id="O5" value="211"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.190" lower_limit="0.180" upper_limit="0.200"/>
                    <measurement group_id="O2" value="0.186" lower_limit="0.176" upper_limit="0.196"/>
                    <measurement group_id="O3" value="0.201" lower_limit="0.191" upper_limit="0.211"/>
                    <measurement group_id="O4" value="0.040" lower_limit="0.022" upper_limit="0.058"/>
                    <measurement group_id="O5" value="0.167" lower_limit="0.149" upper_limit="0.184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 on Day 1, 30 Minutes, Time to Onset of Action Determination</title>
        <description>Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.</description>
        <time_frame>Day 1 - 30 Minutes</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BFF MDI 320/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 320/9.6 μg</description>
          </group>
          <group group_id="O2">
            <title>BFF MDI 160/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 160/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI 9.6 μg</title>
            <description>Formoterol Fumarate Metered Dose Inhalation 9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>BD MDI 320 μg</title>
            <description>Budesonide Metered Dose Inhalation 320 μg</description>
          </group>
          <group group_id="O5">
            <title>Symbicort TBH 400/12 μg</title>
            <description>Symbicort Turbuhaler 400/12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 on Day 1, 30 Minutes, Time to Onset of Action Determination</title>
          <description>Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.</description>
          <population>mITT</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="648"/>
                <count group_id="O2" value="627"/>
                <count group_id="O3" value="638"/>
                <count group_id="O4" value="203"/>
                <count group_id="O5" value="214"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.207" lower_limit="0.196" upper_limit="0.217"/>
                    <measurement group_id="O2" value="0.207" lower_limit="0.196" upper_limit="0.218"/>
                    <measurement group_id="O3" value="0.215" lower_limit="0.205" upper_limit="0.226"/>
                    <measurement group_id="O4" value="0.047" lower_limit="0.028" upper_limit="0.066"/>
                    <measurement group_id="O5" value="0.190" lower_limit="0.172" upper_limit="0.209"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 on Day 1, 1 Hour, Time to Onset of Action Determination</title>
        <description>Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.</description>
        <time_frame>Day 1 - 1 Hour</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BFF MDI 320/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 320/9.6 μg</description>
          </group>
          <group group_id="O2">
            <title>BFF MDI 160/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 160/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI 9.6 μg</title>
            <description>Formoterol Fumarate Metered Dose Inhalation 9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>BD MDI 320 μg</title>
            <description>Budesonide Metered Dose Inhalation 320 μg</description>
          </group>
          <group group_id="O5">
            <title>Symbicort TBH 400/12 μg</title>
            <description>Symbicort Turbuhaler 400/12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 on Day 1, 1 Hour, Time to Onset of Action Determination</title>
          <description>Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.</description>
          <population>mITT</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="649"/>
                <count group_id="O2" value="628"/>
                <count group_id="O3" value="640"/>
                <count group_id="O4" value="204"/>
                <count group_id="O5" value="215"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.225" lower_limit="0.213" upper_limit="0.236"/>
                    <measurement group_id="O2" value="0.221" lower_limit="0.210" upper_limit="0.233"/>
                    <measurement group_id="O3" value="0.236" lower_limit="0.225" upper_limit="0.248"/>
                    <measurement group_id="O4" value="0.053" lower_limit="0.033" upper_limit="0.073"/>
                    <measurement group_id="O5" value="0.211" lower_limit="0.191" upper_limit="0.231"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 on Day 1, 2 Hours, Time to Onset of Action Determination</title>
        <description>Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.</description>
        <time_frame>Day 1 - 2 Hours</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BFF MDI 320/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 320/9.6 μg</description>
          </group>
          <group group_id="O2">
            <title>BFF MDI 160/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 160/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI 9.6 μg</title>
            <description>Formoterol Fumarate Metered Dose Inhalation 9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>BD MDI 320 μg</title>
            <description>Budesonide Metered Dose Inhalation 320 μg</description>
          </group>
          <group group_id="O5">
            <title>Symbicort TBH 400/12 μg</title>
            <description>Symbicort Turbuhaler 400/12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 on Day 1, 2 Hours, Time to Onset of Action Determination</title>
          <description>Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.</description>
          <population>mITT</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="649"/>
                <count group_id="O2" value="629"/>
                <count group_id="O3" value="636"/>
                <count group_id="O4" value="205"/>
                <count group_id="O5" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.253" lower_limit="0.241" upper_limit="0.265"/>
                    <measurement group_id="O2" value="0.234" lower_limit="0.222" upper_limit="0.247"/>
                    <measurement group_id="O3" value="0.244" lower_limit="0.231" upper_limit="0.256"/>
                    <measurement group_id="O4" value="0.063" lower_limit="0.042" upper_limit="0.085"/>
                    <measurement group_id="O5" value="0.221" lower_limit="0.200" upper_limit="0.243"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>FEV1 on Day 1, 4 Hours, Time to Onset of Action Determination</title>
        <description>Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.</description>
        <time_frame>Day 1 - 4 Hours</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BFF MDI 320/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 320/9.6 μg</description>
          </group>
          <group group_id="O2">
            <title>BFF MDI 160/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 160/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI 9.6 μg</title>
            <description>Formoterol Fumarate Metered Dose Inhalation 9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>BD MDI 320 μg</title>
            <description>Budesonide Metered Dose Inhalation 320 μg</description>
          </group>
          <group group_id="O5">
            <title>Symbicort TBH 400/12 μg</title>
            <description>Symbicort Turbuhaler 400/12 μg</description>
          </group>
        </group_list>
        <measure>
          <title>FEV1 on Day 1, 4 Hours, Time to Onset of Action Determination</title>
          <description>Time to onset of action Day 1 was evaluated by calculating change from baseline in FEV1 at each post-dose timepoint (5min, 15min, 30min, 1hr, 2hr, and 4hr), then comparing each treatment to BD MDI 320 ug. The first timepoint a statistically significant difference from BD MDI 320 ug of ≥100mL was determined to be time of onset for that treatment.</description>
          <population>mITT</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="651"/>
                <count group_id="O2" value="630"/>
                <count group_id="O3" value="634"/>
                <count group_id="O4" value="201"/>
                <count group_id="O5" value="217"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.230" lower_limit="0.216" upper_limit="0.243"/>
                    <measurement group_id="O2" value="0.215" lower_limit="0.202" upper_limit="0.229"/>
                    <measurement group_id="O3" value="0.212" lower_limit="0.199" upper_limit="0.226"/>
                    <measurement group_id="O4" value="0.073" lower_limit="0.049" upper_limit="0.097"/>
                    <measurement group_id="O5" value="0.209" lower_limit="0.186" upper_limit="0.232"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Substudy: 12-hour PFT Endpoint FEV1 AUC0-12</title>
        <description>Substudy: 12-hour PFT (Pulmonary Function Test) endpoint FEV1 (Forced Expiratory Volume) AUC0-12 (Area under the Curve 0-12). Changes from baseline in FEV1 AUC0-12 were normalized by taking the area under the curve value and dividing by the length of time under consideration. This normalization represents a weighted average of the change from baseline in FEV1 over the 12-hour period.</description>
        <time_frame>at Week 12</time_frame>
        <population>mITT</population>
        <group_list>
          <group group_id="O1">
            <title>BFF MDI 320/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 320/9.6 μg</description>
          </group>
          <group group_id="O2">
            <title>BFF MDI 160/9.6 μg</title>
            <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 160/9.6 μg</description>
          </group>
          <group group_id="O3">
            <title>FF MDI 9.6 μg</title>
            <description>Formoterol Fumarate Metered Dose Inhalation 9.6 μg</description>
          </group>
          <group group_id="O4">
            <title>BD MDI 320 μg</title>
            <description>Budesonide Metered Dose Inhalation 320 μg</description>
          </group>
        </group_list>
        <measure>
          <title>Substudy: 12-hour PFT Endpoint FEV1 AUC0-12</title>
          <description>Substudy: 12-hour PFT (Pulmonary Function Test) endpoint FEV1 (Forced Expiratory Volume) AUC0-12 (Area under the Curve 0-12). Changes from baseline in FEV1 AUC0-12 were normalized by taking the area under the curve value and dividing by the length of time under consideration. This normalization represents a weighted average of the change from baseline in FEV1 over the 12-hour period.</description>
          <population>mITT</population>
          <units>Liter</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="160"/>
                <count group_id="O2" value="167"/>
                <count group_id="O3" value="189"/>
                <count group_id="O4" value="47"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.135" lower_limit="0.107" upper_limit="0.163"/>
                    <measurement group_id="O2" value="0.124" lower_limit="0.097" upper_limit="0.152"/>
                    <measurement group_id="O3" value="0.117" lower_limit="0.089" upper_limit="0.145"/>
                    <measurement group_id="O4" value="0.024" lower_limit="-0.028" upper_limit="0.075"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse events were collected from the time the subject signed informed consent throughout the treatment period and up to 14 days following the last dose of study drug</time_frame>
      <desc>Serious Adverse Events were collected from the time the subject signed informed consent throughout the treatment period and up to approximately 30 weeks, which includes screening and follow up (14 days after last dose of study drug).</desc>
      <group_list>
        <group group_id="E1">
          <title>BFF MDI 320/9.6 μg</title>
          <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 320/9.6 μg</description>
        </group>
        <group group_id="E2">
          <title>BFF MDI 160/9.6 μg</title>
          <description>Budesonide Formoterol Fumarate Metered Dose Inhalation 160/9.6 μg</description>
        </group>
        <group group_id="E3">
          <title>FF MDI 9.6 μg</title>
          <description>Formoterol Fumarate Metered Dose Inhalation 9.6 μg</description>
        </group>
        <group group_id="E4">
          <title>BD MDI 320 μg</title>
          <description>Budesonide Metered Dose Inhalation 320 μg</description>
        </group>
        <group group_id="E5">
          <title>Symbicort TBH 400/12 μg</title>
          <description>Symbicort Turbuhaler 400/12 μg</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="637"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="644"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="42" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="637"/>
                <counts group_id="E3" subjects_affected="72" subjects_at_risk="644"/>
                <counts group_id="E4" subjects_affected="15" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="20" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Atrial fibrillation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="637"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="644"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Acute myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="637"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Angina unstable</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Atrial flutter</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cardiac failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cardiac failure chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Myocardial ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Atrioventricular block complete</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cardiac arrest</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Coronary artery disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Arteriosclerosis coronary artery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Congestive cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Coronary artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Myocardial infarction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Small intestinal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title vocab="MedDRa">Colitis ischaemic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Diverticulum intestinal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Gastrointestinal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Inflammatory bowel disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pancreatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Strangulated umbilical hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Upper gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Incarcerated hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Sudden cardiac death</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bile duct stone</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cholecystitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="655"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="637"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Abdominal hernia gangrenous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Breast abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Acetabulum fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Dural tear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Femur fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Forearm fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Radius fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Vascular pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Skull fractured base</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Cachexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Diabetes with hyperosmolarity</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Electrolyte imbalance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Adenocarcinoma of colon</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Brain cancer metastatic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Breast cancer male</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bronchial carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Gastric neoplasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Mesothelioma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Metastases to liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Metastatic carcinoma of the bladder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Non-small cell lung cancer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pancreatic carcinoma metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Prostate cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Ischaemic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Transient ischaemic attack</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Carotid artery stenosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Embolic stroke</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Epilepsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Intracranial aneurysm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title vocab="MedDRa">Syncope</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Device battery issue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Mental status changes</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypertonic bladder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Renal tubular necrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Renal cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Prostatic haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="655"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="637"/>
                <counts group_id="E3" events="35" subjects_affected="29" subjects_at_risk="644"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Acute respiratory failure</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="655"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="637"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pulmonary embolism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Respiratory failure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Pleural effusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Arteriosclerosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Hypertensive emergency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Peripheral artery thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Peripheral ischaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis superficial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="655"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="637"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>2</frequency_threshold>
        <default_vocab>MedDRA</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="240" subjects_at_risk="655"/>
                <counts group_id="E2" subjects_affected="201" subjects_at_risk="637"/>
                <counts group_id="E3" subjects_affected="219" subjects_at_risk="644"/>
                <counts group_id="E4" subjects_affected="75" subjects_at_risk="206"/>
                <counts group_id="E5" subjects_affected="57" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="655"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="637"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="644"/>
                <counts group_id="E4" events="6" subjects_affected="5" subjects_at_risk="206"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="655"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="637"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="644"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="206"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="46" subjects_affected="40" subjects_at_risk="655"/>
                <counts group_id="E2" events="44" subjects_affected="40" subjects_at_risk="637"/>
                <counts group_id="E3" events="46" subjects_affected="43" subjects_at_risk="644"/>
                <counts group_id="E4" events="18" subjects_affected="17" subjects_at_risk="206"/>
                <counts group_id="E5" events="18" subjects_affected="14" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="27" subjects_affected="25" subjects_at_risk="655"/>
                <counts group_id="E2" events="24" subjects_affected="21" subjects_at_risk="637"/>
                <counts group_id="E3" events="20" subjects_affected="20" subjects_at_risk="644"/>
                <counts group_id="E4" events="7" subjects_affected="5" subjects_at_risk="206"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="655"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="637"/>
                <counts group_id="E3" events="36" subjects_affected="30" subjects_at_risk="644"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E5" events="6" subjects_affected="6" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="655"/>
                <counts group_id="E2" events="15" subjects_affected="14" subjects_at_risk="637"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="644"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="206"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="655"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="637"/>
                <counts group_id="E3" events="10" subjects_affected="10" subjects_at_risk="644"/>
                <counts group_id="E4" events="4" subjects_affected="4" subjects_at_risk="206"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="655"/>
                <counts group_id="E2" events="10" subjects_affected="9" subjects_at_risk="637"/>
                <counts group_id="E3" events="13" subjects_affected="12" subjects_at_risk="644"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E5" events="5" subjects_affected="5" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="655"/>
                <counts group_id="E2" events="14" subjects_affected="13" subjects_at_risk="637"/>
                <counts group_id="E3" events="19" subjects_affected="18" subjects_at_risk="644"/>
                <counts group_id="E4" events="3" subjects_affected="3" subjects_at_risk="206"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="15" subjects_affected="14" subjects_at_risk="655"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="637"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="644"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="206"/>
                <counts group_id="E5" events="8" subjects_affected="8" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="27" subjects_affected="19" subjects_at_risk="655"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="637"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="644"/>
                <counts group_id="E4" events="4" subjects_affected="3" subjects_at_risk="206"/>
                <counts group_id="E5" events="3" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="655"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="637"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="644"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="206"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="655"/>
                <counts group_id="E2" events="15" subjects_affected="15" subjects_at_risk="637"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="644"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="206"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="655"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="637"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="644"/>
                <counts group_id="E4" events="7" subjects_affected="7" subjects_at_risk="206"/>
                <counts group_id="E5" events="3" subjects_affected="3" subjects_at_risk="219"/>
              </event>
              <event>
                <sub_title vocab="medDRA">Dysphonia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="16" subjects_at_risk="655"/>
                <counts group_id="E2" events="13" subjects_affected="13" subjects_at_risk="637"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="644"/>
                <counts group_id="E4" events="2" subjects_affected="2" subjects_at_risk="206"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="14" subjects_affected="14" subjects_at_risk="655"/>
                <counts group_id="E2" events="22" subjects_affected="22" subjects_at_risk="637"/>
                <counts group_id="E3" events="15" subjects_affected="15" subjects_at_risk="644"/>
                <counts group_id="E4" events="5" subjects_affected="5" subjects_at_risk="206"/>
                <counts group_id="E5" events="5" subjects_affected="4" subjects_at_risk="219"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Drafts of any and all publications or presentations of this study must be submitted at least 30 days prior to submission for publication or presentation to Pearl Therapeutics for review, approval, and to ensure consistency. Pearl Therapeutics has the right to request appropriate modification to correct facts and to represent it's opinions, or the opinions of the publication committee, if these differ with the proposed publication.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Paul M. Dorinsky, MD</name_or_title>
      <organization>Pearl Therapeutics, a Member of the AstraZeneca Group</organization>
      <phone>650-305-2600</phone>
      <email>paul.dorinsky1@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

